Drug Trial Radar · NCT05769010
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Last checked: Nov 20, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Mar 31, 2023
Primary completion
Dec 30, 2028
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Henan Cancer HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Mar 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aimed to evaluate the use of SHR-A1811 in HER2-expression Advanced Breast Cancer patients with brain metastases.
Conditions
- Metastatic Breast Cancer
Interventions
SHR-A1811Drug
SHR-A1811: intravenous
PyrotinibDrug
Pyrotinib: oral
BevacizumabDrug
Bevacizumab: intravenous
AdebelizumabDrug
Adebelizumab: intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- CNS-ORR by investigatorTime frame: 2 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.